600211 西藏药业
2025/09 - 九个月2024/122023/122022/122021/12

盈利能力分析
净资产收益率 ROE (%)19.32728.95225.20013.1108.026
总资产报酬率 ROA (%)13.66522.52418.4399.3606.194
投入资产回报率 ROIC (%)15.69826.10021.71111.0287.230

边际利润分析
销售毛利率 (%)93.73394.21895.05294.25889.562
营业利润率 (%)38.86041.34628.68518.18912.008
息税前利润/营业总收入 (%)35.74539.36627.58118.30712.232
净利润/营业总收入 (%)34.74537.66225.85114.6919.961

收益指标分析
经营活动净收益/利润总额(%)94.32281.680119.799160.019222.558
价值变动净收益/利润总额(%)0.744-0.337-18.937-1.54157.474
营业外收支净额/利润总额(%)-0.177-0.726-0.100-0.272-0.765

偿债能力分析
流动比率 (X)3.0204.6572.8732.6431.966
速动比率 (X)2.8934.4822.7792.5451.843
资产负债率 (%)32.24716.75126.45826.07230.443
带息债务/全部投入资本 (%)18.8905.97212.56513.21015.985
股东权益/带息债务 (%)376.1101,563.149689.815647.811516.180
股东权益/负债合计 (%)189.353492.663275.561281.766227.218
利息保障倍数 (X)-11.732-23.418-25.643108.98638.756

营运能力分析
应收账款周转天数 (天)57.62375.53663.03864.69167.692
存货周转天数 (天)318.453272.415245.342291.134167.867